Non-Alcoholic Steatohepatitis Clinical Trials Market Forecast to Reach USD 5.81 Billion by 2035 at 7.0% CAGR

Non-Alcoholic Steatohepatitis Clinical Trials Market size

DE, UNITED STATES, March 20, 2026 /EINPresswire.com/ -- The global Non-Alcoholic Steatohepatitis Clinical Trials Market is projected to grow from USD 2.96 billion in 2025 to USD 5.81 billion by 2035, expanding at a CAGR of 7.0% during the forecast period. Rising prevalence of NASH, coupled with increasing investments in drug development and clinical research, is driving sustained market momentum. The market’s importance continues to grow as pharmaceutical companies intensify efforts to address unmet therapeutic needs in liver disease.

Market snapshot: global market 2026 - 2036

Market size 2026: Not specified
Market size 2036: USD 5.81 billion (by 2035 end)
CAGR (2025–2035): 7.0%
Leading product segments: Interventional trials (45.9% share in 2025), Phase 3 trials (40.2%)
Leading material type: Not specified
Leading end use: Not specified
Key growth regions: North America, Europe, Asia-Pacific
Top companies: Pfizer Inc., Novartis AG, Icon Plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly, GSK plc., Novo Nordisk, Gilead Sciences Inc., Viking Therapeutics

Market Momentum (YoY Path)

The Non-Alcoholic Steatohepatitis Clinical Trials Market demonstrates a steady upward trajectory, supported by rising clinical activity and research funding. In 2025, the market is valued at USD 2.96 billion and is projected to expand consistently through the forecast period, reaching USD 5.81 billion by 2035. Growth remains stable across key milestone years including 2028, 2030, 2031, and 2033, reflecting continuous pipeline expansion and increasing patient recruitment. By 2035, the market achieves its peak valuation within the forecast horizon, maintaining a CAGR of 7.0%.

Why the Market is Growing

The Non-Alcoholic Steatohepatitis Clinical Trials Market is expanding due to the increasing global burden of obesity, type 2 diabetes, and metabolic syndrome. These conditions are strongly linked to NASH, creating a growing patient pool and urgent need for effective therapies. Rising awareness, lack of approved drugs, and strong investment from both public and private sectors are accelerating clinical trial activity. Regulatory support and advancements in drug discovery are further strengthening market growth.

Drivers, Opportunities, Trends, Challenges

Drivers
The rising prevalence of NASH, driven by increasing obesity and diabetes rates, is a primary growth driver. The disease’s asymptomatic progression and risk of severe complications such as cirrhosis and liver cancer further intensify demand for clinical trials.

Opportunities
Growing investments from governments and private organizations are creating strong opportunities for innovation. Funding supports biomarker development, preclinical studies, and advanced clinical trials, accelerating drug discovery.

Trends
A key trend in the Non-Alcoholic Steatohepatitis Clinical Trials Market is the expansion of late-stage pipelines, particularly Phase 3 trials. The use of non-invasive diagnostics and digital health tools is improving trial efficiency and patient recruitment.

Challenges
High costs associated with clinical trials present a major challenge. Long study durations, complex diagnostics, and large patient requirements increase financial burdens and create barriers for smaller companies.

Competitive Landscape

The Non-Alcoholic Steatohepatitis Clinical Trials Market is highly competitive, with a mix of Tier 1, Tier 2, and Tier 3 players. Tier 1 companies account for 56.3% of the market, leveraging strong R&D capabilities and global reach. Tier 2 players hold 31.7% share and focus on niche markets with competitive pricing. Tier 3 companies contribute to market diversity with specialized offerings. Key players include Pfizer Inc., Novartis AG, Icon Plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly, GSK plc., Novo Nordisk, Gilead Sciences Inc., and Viking Therapeutics. Strategic collaborations, acquisitions, and research investments remain core competitive strategies.

Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-15802

Scope of the Report

Quantitative units: USD billion / USD million for value
Study design segmentation: Interventional, Observational, Expanded Access
Phase segmentation: Phase 1, Phase 2, Phase 3, Phase 4
Regions: North America, Latin America, Europe, Asia-Pacific, Middle East & Africa
Countries: USA, Germany, France, UK, China, India, Brazil, and others
Key companies profiled: Pfizer Inc., Novartis AG, Icon Plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly, GSK plc., Novo Nordisk, Gilead Sciences Inc., Viking Therapeutics

FAQ

What is the future outlook for the Non-Alcoholic Steatohepatitis Clinical Trials Market?
The market is projected to grow at a CAGR of 7.0% from 2025 to 2035.

What was the market size in 2024?
The market stood at USD 2,829.5 million in 2024.

What will be the market size by 2035?
It is expected to reach USD 5.81 billion by 2035.

Which country shows strong growth potential?
India is expected to grow at a CAGR of 9.0%, while China is projected at 8.3%.

Who are the key players in the market?
Leading companies include Pfizer Inc., Novartis AG, Icon Plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly, GSK plc., Novo Nordisk, Gilead Sciences Inc., and Viking Therapeutics.

Explore More Related Studies Published by FMI Research:

Disease-Modifying MS Therapies Market: https://www.futuremarketinsights.com/reports/disease-modifying-ms-therapies-market

Vitamins and Minerals Based Injectables Market: https://www.futuremarketinsights.com/reports/vitamins-and-minerals-based-injectables-market

Battery Powered Surgical Drill Market: https://www.futuremarketinsights.com/reports/battery-powered-surgical-drill-market

Cytotoxic Chemotherapy Market: https://www.futuremarketinsights.com/reports/cytotoxic-chemotherapy-market

Targeted Oncology Biologics Market: https://www.futuremarketinsights.com/reports/targeted-oncology-biologics-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Sudip Saha
Future Market Insights Inc.
+1 347-918-3531
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.